Art. -Nr.: HY-19741

Copy Link Print Information

A-1331852

55 Cited Publications

Kundenbewertung

Based on 55 publication(s) in Google Scholar

A-1331852 is an orally available BCL-XL selective inhibitor with a K_i of less than 10 pM.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.93%
CAS. Nr.: 1430844-80-6
Formel: C₃₈H₃₈N₆O₃S
Molecular Weight:658.81

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

A-1331852 Chemical Structure

CAS. Nr.: 1430844-80-6

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (55)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

A-1331852 is an orally available BCL-XL selective inhibitor with a K_i of less than 10 pM.

IC₅₀ & Target^[1]

Bcl-xL

0.01 nM (Ki)

Bcl-W

4 nM (Ki)

Bcl-2

6 nM (Ki)

Mcl-1

142 nM (Ki)

Alle Bcl-2 Family Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
MOLT-4	EC₅₀	>5000 nM Compound: A-1331852	Antiproliferative activity against Bcl-2 dependent human MOLT-4 cells assessed as reduction in cell viability by measuring effect concentration by CellTiter-Glo reagent based assay Antiproliferative activity against Bcl-2 dependent human MOLT-4 cells assessed as reduction in cell viability by measuring effect concentration by CellTiter-Glo reagent based assay	[PMID: 25787766]
MOLT-4	EC₅₀	6 nM Compound: A-1331852	Antiproliferative activity against Bcl-xl dependent human MOLT-4 cells assessed as reduction in cell viability by measuring effect concentration by CellTiter-Glo reagent based assay Antiproliferative activity against Bcl-xl dependent human MOLT-4 cells assessed as reduction in cell viability by measuring effect concentration by CellTiter-Glo reagent based assay	[PMID: 25787766]
MOLT-4	EC₅₀	6 nM Compound: 33; A-1331852	Cytotoxicity against human Bcl-XL dependant MOLT4 cells by cell based assay Cytotoxicity against human Bcl-XL dependant MOLT4 cells by cell based assay	[PMID: 26988306]
MOLT-4	EC₅₀	6.3 nM Compound: 13, A-1331852	Antiproliferative activity against human MOLT4 cells assessed as reduction in cell viability after 48 hrs in presence of 10% human serum by CellTiter-Glo luminescent assay Antiproliferative activity against human MOLT4 cells assessed as reduction in cell viability after 48 hrs in presence of 10% human serum by CellTiter-Glo luminescent assay	[PMID: 33062160]
RS4-11	EC₅₀	>5 μM Compound: 33; A-1331852	Cytotoxicity against human Bcl-2 dependant RS4:11 cells by cell based assay Cytotoxicity against human Bcl-2 dependant RS4:11 cells by cell based assay	[PMID: 26988306]
RS4-11	EC₅₀	>5000 nM Compound: 13, A-1331852	Cytotoxicity against human RS4:11 cells assessed as reduction in cell viability after 48 hrs in presence of 10% human serum by CellTiter-Glo luminescent assay Cytotoxicity against human RS4:11 cells assessed as reduction in cell viability after 48 hrs in presence of 10% human serum by CellTiter-Glo luminescent assay	[PMID: 33062160]

In Vitro

A-1331852 selectively disrupts BCL-XL–BIM complexes and induces the hallmarks of apoptosis in BCL-XL–dependent Molt-4 cells with IC₅₀s in the low nanomolar range but does not affect MEF cells lacking BAK or BAX. In CellTiter-Glo cell viability assay, A-1331852 inhibits NCI-H847, NCI-H1417, SET-2, HEL, OCI-M2 with EC₅₀ values of 3, 7, 80, 120 and 100 nM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

A-1331852 demonstrates antitumor efficacy in the Molt-4 xenograft model, inducing tumor regressions as a single agent. Additionally, A-1331852 combines with venetoclax to recapitulate the efficacy of navitoclax in the NCI-H1963.FP5 xenograft model of SCLC. A-1331852 significantly inhibits tumor growth in seven subcutaneous xenograft models of solid tumors, including breast cancer, NSCLC, and ovarian cancer^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 1430844-80-6
Appearance Solid
Molecular Weight 658.81
Formel C₃₈H₃₈N₆O₃S
Color White to light yellow
SMILES

O=C(C1=NC(N2CC3=C(C=CC=C3C(NC4=NC5=CC=CC=C5S4)=O)CC2)=CC=C1C6=C(C)N(CC7(C8)CC9CC8CC(C9)C7)N=C6)O
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (55)

All IHCIn Vivo ImagingCell Proliferation/Viability AssayWBBio/Physico-chemical AssayFlow Cytometry

Sort by:

Journal Impact Factor

Nature

Dynamic antigen expression and cytotoxic T cell resistance in HIV reservoir clones. [Abstract]

2026 May;653(8115):850-860. PMID: 41735521
Nature

R-loop-derived cytoplasmic RNA-DNA hybrids activate an immune response. [Abstract]

2023 Jan;613(7942):187-194. PMID: 36544021
Nature

Nuclear sensing of breaks in mitochondrial DNA enhances immune surveillance. [Abstract]

2021 Mar;591(7850):477-481. PMID: 33627873
Cancer Cell

CCL3 is produced by aged neutrophils across cancers and promotes tumor growth. [Abstract]

2026 Feb 5:S1535-6108(26)00045-0. PMID: 41650972
Cell

Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis. [Abstract]

2022 Apr 28;185(9):1521-1538.e18. PMID: 35447071

A-1331852 purchased from MedChemExpress. Usage Cited in: Cell. 2022 Apr 28;185(9):1521-1538.e18. [Abstract]

Sensitivity of resting and pre-activated NK cells to BCL-XL inhibitor (A-1331852; 0-4096 nM; 24 h), as measured by annexin V staining.
Nat Cancer

Targeting a lineage-specific PI3Kɣ-Akt signaling module in acute myeloid leukemia using a heterobifunctional degrader molecule. [Abstract]

2024 Jul;5(7):1082-1101. PMID: 38816660

A-1331852 purchased from MedChemExpress. Usage Cited in: Nat Cancer. 2024 Jul;5(7):1082-1101. [Abstract]

Growth inhibition curves (left panel), IC50 values, and AUCs (right panel) of OCI-AML2 cells treated with DMSO or 500nM ARM165 in combination with increasing doses (10-10000 nM）of either venetoclax, S63845, WEHI-539 and A-1331852. Error bars represent mean ± SD of three biological replicates composed of seven technical repeats after three days of seeding.
Nat Cancer

CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity. [Abstract]

2021 Jan;2(1):34-48. PMID: 33997789

A-1331852 purchased from MedChemExpress. Usage Cited in: Nat Cancer. 2021 Jan;2(1):34-48. [Abstract]

Representative cleaved caspase-3 staining and quantification of cleaved caspase-3-positive area in PDX 14–07 tumors treated with vehicle (n=21), abemaciclib (n=18), A-1331852 (25 mg/kg, p.o., every 12 hours, 3 doses in total) (n=15), or the combination (n=18). Mean ± s.d. of positively stained area are shown. P values were determined by Kruskal-Wallis, Dunn’s multiple comparisons test. Scale bars represent 100 μm.
Cell Res

Antagonizing the irreversible thrombomodulin-initiated proteolytic signaling alleviates age-related liver fibrosis via senescent cell killing. [Abstract]

2023 Jul;33(7):516-532. PMID: 37169907
Cell Stem Cell

Leukemic stem cell subtypes determine venetoclax resistance and therapeutic vulnerabilities in AML. [Abstract]

2026 Jun 4;33(6):982-999.e8. PMID: 42102807
Nat Commun

Dynamic BH3 profiling identifies pro-apoptotic drug combinations for the treatment of malignant pleural mesothelioma. [Abstract]

2023 May 20;14(1):2897. PMID: 37210412
Cell Death Differ

Senolysis by ABT-263 is associated with inherent apoptotic dependence of cancer cells derived from the non-senescent state. [Abstract]

2025 May;32(5):855-865. PMID: 39706991
J Clin Invest

BCL-2 antagonism sensitizes cytotoxic T cell-resistant HIV reservoirs to elimination ex vivo. [Abstract]

2020 May 1;130(5):2542-2559. PMID: 32027622
Leukemia

Altered RNA export by SF3B1 mutants confers sensitivity to nuclear export inhibition. [Abstract]

2024 Sep;38(9):1894-1905. PMID: 38997434
Sci Adv

Interaction between NF-κB and PLAC8 impairs autophagy providing a survival advantage to prostate cells transformed by cadmium. [Abstract]

2025 Jun 13;11(24):eadv8640. PMID: 40512859
Cell Rep Med

Venetoclax acts as an immunometabolic modulator to potentiate adoptive NK cell immunotherapy against leukemia. [Abstract]

2024 May 16:101580. PMID: 38776913
Cancer Lett

High-content drug screening in zebrafish xenografts reveals high efficacy of dual MCL-1/BCL-XL inhibition against Ewing sarcoma. [Abstract]

2023 Feb 1:554:216028. PMID: 36462556

A-1331852 purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2023 Feb 1:554:216028. [Abstract]

Xenotransplanted zebrafish larvae were treated with A-1331852 (10 μM; 48 h) (1 dpi - 3 dpi). Dot plots show relative changes of tumor area (3 dpi/1 dpi).
Cancer Lett

Stress-induced upregulation of TNFSF4 in cancer-associated fibroblast facilitates chemoresistance of lung adenocarcinoma through inhibiting apoptosis of tumor cells. [Abstract]

2021 Jan 28;497:212-220. PMID: 33132120
Cell Death Dis

2026 Apr 10;17(1):388.
Cell Death Dis

Both direct and indirect suppression of MCL1 synergizes with BCLXL inhibition in preclinical models of gastric cancer. [Abstract]

2025 Mar 12;16(1):170. PMID: 40075071
Cell Death Dis

Novel selective strategies targeting the BCL-2 family to enhance clinical efficacy in ALK-rearranged non-small cell lung cancer. [Abstract]

2025 Mar 20;16(1):194. PMID: 40113795
Cell Death Dis

Integrative single-cell RNA-seq and spatial transcriptomics analyses reveal diverse apoptosis-related gene expression profiles in EGFR-mutated lung cancer. [Abstract]

2024 Aug 9;15(8):580. PMID: 39122703
Cell Death Dis

Fatty acid synthase (FASN) regulates the mitochondrial priming of cancer cells. [Abstract]

2021 Oct 21;12(11):977. PMID: 34675185
Cell Death Dis

Dynamic BH3 profiling identifies active BH3 mimetic combinations in non-small cell lung cancer. [Abstract]

2021 Jul 27;12(8):741. PMID: 34315868
Cell Death Dis

MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells. [Abstract]

2020 Jun 8;11(6):443. PMID: 32513939

A-1331852 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2020 Jun 8;11(6):443. [Abstract]

In A375 cells, knockdown (KD) of MCL1 (shMCL1), BCL2 (shBCL2), BCLW (shBCLW), and BCLXL (shBCLXL) lines are created by shRNA technology. shMCL1 (in presence of ABT-263 or A-1331852) shows significant reduction in cell viability during 48 h drug treatment.

A-1331852 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2020 Jun 8;11(6):443. [Abstract]

Immunoblot with cell lysates collected after 48 h treatment with DMSO, single drugs: S63845 (156 nM) and A-1331852 (156 nM), or combinations, and probed for PARP. Both combinations increased the cleaved product of PARP. Molecular weight markers are in kDa.
Cell Death Dis

XPO1 inhibitor KPT-330 synergizes with Bcl-xL inhibitor to induce cancer cell apoptosis by perturbing rRNA processing and Mcl-1 protein synthesis. [Abstract]

2019 May 21;10(6):395. PMID: 31113936
NPJ Precis Oncol

Refined high-content imaging-based phenotypic drug screening in zebrafish xenografts. [Abstract]

2023 May 18;7(1):44. PMID: 37202469
J Transl Med

Parthenolide improves sepsis-induced coagulopathy by inhibiting mitochondrial-mediated apoptosis in vascular endothelial cells through BRD4/BCL-xL pathway. [Abstract]

2025 Jan 17;23(1):80. PMID: 39825405
Blood Adv

BH3 mimetic drugs overcome the microenvironment-induced resistance to crizotinib in ALK+ anaplastic large cell lymphoma. [Abstract]

2025 Jul 2:bloodadvances.2024015322. PMID: 40601898
Antioxidants (Basel)

Antioxidants Threaten Multikinase Inhibitor Efficacy against Liver Cancer by Blocking Mitochondrial Reactive Oxygen Species. [Abstract]

2021 Aug 24;10(9):1336. PMID: 34572967
Biochem Pharmacol

Senolytic elimination of therapy-induced senescent cells by ABT-263 improves chemotherapeutic efficacy in esophageal squamous cell carcinoma. [Abstract]

2025 Dec 19:245:117659. PMID: 41423036
Biochem Pharmacol

BCL2L1 inhibitor A-1331852 inhibits MCL1 transcription and triggers apoptosis in acute myeloid leukemia cells. [Abstract]

2023 Sep:215:115738. PMID: 37562509
Pharmaceuticals (Basel)

A Novel Regimen for Treating Melanoma: MCL1 Inhibitors and Azacitidine. [Abstract]

2021 Jul 30;14(8):749. PMID: 34451846
iScience

Developing therapeutic strategies to target MCL1 and BCLXL in lethal prostate cancer. [Abstract]

2025 Nov 10;28(12):113985. PMID: 41438049
J Biotechnol

FRET two-hybrid assay-based target drug screening in living cells. [Abstract]

2025 Nov 12:410:1-9. PMID: 41238124
Sci Rep

Low BCL-xL expression in triple-negative breast cancer cells favors chemotherapy efficacy, and this effect is limited by cancer-associated fibroblasts. [Abstract]

2024 Jun 19;14(1):14177. PMID: 38898061
J Photochem Photobiol B

Differential UVC radiation sensitivity in multidrug-resistant l1210 cells: Insights into p53 and Bcl-XL expression/function. [Abstract]

2025 Oct:271:113229. PMID: 40752104
J Periodontal Res

ZNF862 induces cytostasis and apoptosis via the p21-RB1 and Bcl-xL-Caspase 3 signaling pathways in human gingival fibroblasts. [Abstract]

2024 Jun;59(3):599-610. PMID: 38482719
Discov Oncol

Dual inhibition of anti-apoptotic proteins BCL-XL and MCL-1 enhances cytotoxicity of Nasopharyngeal carcinoma cells. [Abstract]

2022 Feb 3;13(1):9. PMID: 35201512
J Biophotonics

Automated FRET Two-Hybrid Analysis. [Abstract]

2025 Apr 23:e70033. PMID: 40268497
Biochem Biophys Res Commun

BID- and BAX-mediated mitochondrial pathway dominates A-1331852-induced apoptosis in senescent A549 cells. [Abstract]

2022 Oct 30:627:160-167. PMID: 36041325
Biochem Biophys Res Commun

BAK plays a key role in A-1331852-induced apoptosis in senescent chondrocytes. [Abstract]

2022 Jun 18;609:93-99. PMID: 35421634
Biochem Biophys Rep

Co-inhibition of BCL-XL and MCL-1 with selective BCL-2 family inhibitors enhances cytotoxicity of cervical cancer cell lines. [Abstract]

2020 Apr 22;22:100756. PMID: 32346617
bioRxiv

2026 Jun 26.
bioRxiv

2026 Feb 20.
University of Washington

2025.
bioRxiv

2025 April 18.
bioRxiv

2025 April 10.
bioRxiv

2025 February 15.
Res Sq

2025 Feb 23.
bioRxiv

2023 Sep 28.
University of Gothenburg

2023 Jun 27.
bioRxiv

2023 Apr 23.
University of Colorado

2020 Dec.
University of Michigan

2020 May.
bioRxiv

2020 Feb.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 50 mg/mL (75.89 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : 4 mg/mL (6.07 mM; ultrasonic and warming and heat to 60°C)

H₂O : < 0.1 mg/mL (insoluble)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.5179 mL

7.5894 mL

15.1789 mL

5 mM

0.3036 mL

1.5179 mL

3.0358 mL

10 mM

0.1518 mL

0.7589 mL

1.5179 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 2.5% DMSO 10% Ethanol 27.5% PEG300 60% Phosal 50 PG

Solubility: ≥ 2.5 mg/mL (3.79 mM); Clear solution

Protocol 2

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 2.08 mg/mL (3.16 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 3

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.08 mg/mL (3.16 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 4

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (3.16 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Cell Assay^[1]

SCLC and AML cell lines are incubated with increasing concentrations of navitoclax, venetoclax, or A-1155463 for 48 hours before assessing cell viability. Cell killing EC₅₀ values are calculated^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[1]

Mice: The growth inhibition of established tumors in SCID-bg mice is studied. A-1331852 is administered orally daily for 14 days at 25 mg/kg and RP-56976 is administered intravenously at 7.5 mg/kg. The change of tumor volume is monitored daily^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (283 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Leverson JD, et al. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci Transl Med. 2015 Mar 18;7(279):279ra40. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
Ethanol / DMSO	1 mM	1.5179 mL	7.5894 mL	15.1789 mL	37.9472 mL
Ethanol / DMSO	5 mM	0.3036 mL	1.5179 mL	3.0358 mL	7.5894 mL
DMSO	10 mM	0.1518 mL	0.7589 mL	1.5179 mL	3.7947 mL
	15 mM	0.1012 mL	0.5060 mL	1.0119 mL	2.5298 mL
	20 mM	0.0759 mL	0.3795 mL	0.7589 mL	1.8974 mL
	25 mM	0.0607 mL	0.3036 mL	0.6072 mL	1.5179 mL
	30 mM	0.0506 mL	0.2530 mL	0.5060 mL	1.2649 mL
	40 mM	0.0379 mL	0.1897 mL	0.3795 mL	0.9487 mL
	50 mM	0.0304 mL	0.1518 mL	0.3036 mL	0.7589 mL
	60 mM	0.0253 mL	0.1265 mL	0.2530 mL	0.6325 mL

Keywords

A-1331852

55 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

A-1331852

Apoptosis Compound Library

Anti-Cancer Compound Library

Orally Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Blood Cancer Compound Library

Mitochondria-Targeted Compound Library

Targeted Diversity Library

Heterocyclic Compound Library

Highly Selective Inhibitors Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Mitophagy Compound Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) A-1331852

Alle Bcl-2 Family Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (55)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

A-1331852

Apoptosis Compound Library

Anti-Cancer Compound Library

Orally Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Blood Cancer Compound Library

Mitochondria-Targeted Compound Library

Targeted Diversity Library

Heterocyclic Compound Library

Highly Selective Inhibitors Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Mitophagy Compound Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) A-1331852

Alle Bcl-2 Family Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (55)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

A-1331852 Related Classifications

HY-19741 Related Classifications